Results 121 to 130 of about 4,505 (178)

Comparative Effect of SGLT2 Inhibitors and GLP-1 Agonists on Glycemic Control in Type 2 Diabetes Mellitus.

J Pharm Bioallied Sci
Prakash V, Gupta S, Singh S, Rawat A, Deshpande AV, Podder A, Jani P.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Saxagliptin

Drugs, 2009
Saxagliptin and its active metabolite M2 are dipeptidyl peptidase-4 inhibitors that improve glycaemic control by preventing the inactivation of the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide. This increases GLP-1 levels, stimulates insulin secretion and reduces postprandial glucagon and glucose ...
Sohita, Dhillon, Juliane, Weber
openaire   +2 more sources

Nephroprotection with saxagliptin.

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia, 2015
The nephroprotective effect of the new anti-diabetic drugs acting on incretin system is suggested by preclinical studies. However, no study evaluating kidney effects of these drugs as primary outcome on the long term has been conducted in patients followed in diabetes centers.
Iazzetta, Nicolangelo, Garofalo, Carlo, Savino, Manuela, Sagliocca, Adelia, Santangelo, Sara, Pacilio, Mario, Liberti, Maria Elena, Camocardi, Andrea, Ambrosca, Camilla, MINUTOLO, Roberto, DE NICOLA, Luca, CONTE, Giuseppe   +11 more
openaire   +2 more sources

Saxagliptin: A novel antiparkinsonian approach

Neuropharmacology, 2015
The emergence of glucagon-like peptide-1 as a crucial contender in modifying neurodegenerative diseases in the preclinical studies has instigated interest in investigating the antiparkinsonian effect of dipeptidyl peptidase (DPP)-4 inhibition. Notably, saxagliptin (SAX), the DPP-4 inhibitor, recently showed efficacy in ameliorating streptozotocin ...
Noha N, Nassar, Muhammad Y, Al-Shorbagy, Hany H, Arab, Dalaal M, Abdallah   +3 more
openaire   +2 more sources

Saxagliptin in type 2 diabetes

Drugs of Today, 2010
Saxagliptin is the latest addition to incretin-based therapies in the management of type 2 diabetes. The oral selective dipeptidyl peptidase 4 (DPP-4) inhibitor is just the second in its class to be approved in the U.S. It has been designed to exert long-lasting yet reversible inhibition of the DPP-4 enzyme, thereby slowing down the inactivation of the
openaire   +2 more sources

Saxagliptin

Reactions Weekly, 2022
openaire   +1 more source

Saxagliptin

RCSB Protein Data Bank, 2017
Jennifer Jiang, Sutapa Ghosh
openaire   +2 more sources

Saxagliptin

Drugs of the Future, 2008
null Cole, P., null Serradell, N., null Bolos, J., null Castaner, R.   +3 more
openaire   +1 more source

Review: Saxagliptin: a review

The British Journal of Diabetes & Vascular Disease, 2010
Modulation of the effects of incretin hormones provides a novel mechanism of action for some of the newer therapies for patients with type 2 diabetes. The selective, reversible dipeptidyl peptidase-4 inhibitor saxagliptin has demonstrated robust improvements in glycaemic control, as monotherapy or as add-on therapy to metformin, sulphonylureas and ...
openaire   +1 more source